712515
O-(3-Carboxypropyl)-O′-[2-(3-mercaptopropionylamino)ethyl]-polyethylene glycol
Mw 3000
Sinónimos:
Polyethylene glycol, α-Mercapto-ω-carboxy-PEG
About This Item
Productos recomendados
![(+)-1,2-Bis[(2S,5S)-2,5-dimethylphospholano]benzene kanata purity](/deepweb/assets/sigmaaldrich/product/structures/319/912/cec7b70f-bf7c-4a96-9f11-a73ae892e34c/640/cec7b70f-bf7c-4a96-9f11-a73ae892e34c.png)
form
powder
Quality Level
mol wt
Mw 3000
reaction suitability
reagent type: cross-linking reagent
Ω-end
thiol
α-end
carboxylic acid
storage temp.
−20°C
¿Está buscando productos similares? Visita Guía de comparación de productos
Categorías relacionadas
Packaging
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Los clientes también vieron
![O-(3-Carboxypropyl)-O′-[2-(3-mercaptopropionylamino)ethyl]-polyethylene glycol Mw 5000](/deepweb/assets/sigmaaldrich/product/structures/271/277/d02536f0-83d7-4416-9cea-f6213e09fe85/640/d02536f0-83d7-4416-9cea-f6213e09fe85.png)
Artículos
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Protocolos
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico